Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
Hemasphere ; 6(5): e0711, 2022 May.
Article in English | MEDLINE | ID: covidwho-1795006

ABSTRACT

Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44-84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (P = 0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort.

3.
HemaSphere ; 6(5), 2022.
Article in English | EuropePMC | ID: covidwho-1787481

ABSTRACT

Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44–84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (P = 0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort.

4.
Leukemia ; 35(12): 3444-3454, 2021 12.
Article in English | MEDLINE | ID: covidwho-1493064

ABSTRACT

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.


Subject(s)
COVID-19/complications , COVID-19/mortality , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , COVID-19/diagnosis , COVID-19/virology , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Leukemia, Lymphocytic, Chronic, B-Cell/virology , Mortality , Prognosis , Risk Factors , SARS-CoV-2 , Severity of Illness Index , Survival Analysis
5.
mSphere ; 6(4): e0024421, 2021 08 25.
Article in English | MEDLINE | ID: covidwho-1329039

ABSTRACT

Recent studies have shown that persistent SARS-CoV-2 infections in immunocompromised patients can trigger the accumulation of an unusual high number of mutations with potential relevance at both biological and epidemiological levels. Here, we report a case of an immunocompromised patient (non-Hodgkin lymphoma patient under immunosuppressive therapy) with a persistent SARS-CoV-2 infection (marked by intermittent positivity) over at least 6 months. Viral genome sequencing was performed at days 1, 164, and 171 to evaluate SARS-CoV-2 evolution. Among the 15 single-nucleotide polymorphisms (SNPs) (11 leading to amino acid alterations) and 3 deletions accumulated during this long-term infection, four amino acid changes (V3G, S50L, N87S, and A222V) and two deletions (18-30del and 141-144del) occurred in the virus Spike protein. Although no convalescent plasma therapy was administered, some of the detected mutations have been independently reported in other chronically infected individuals, which supports a scenario of convergent adaptive evolution. This study shows that it is of the utmost relevance to monitor the SARS-CoV-2 evolution in immunocompromised individuals, not only to identify novel potentially adaptive mutations, but also to mitigate the risk of introducing "hyper-evolved" variants in the community. IMPORTANCE Tracking the within-patient evolution of SARS-CoV-2 is key to understanding how this pandemic virus shapes its genome toward immune evasion and survival. In the present study, by monitoring a long-term COVID-19 immunocompromised patient, we observed the concurrent emergence of mutations potentially associated with immune evasion and/or enhanced transmission, mostly targeting the SARS-CoV-2 key host-interacting protein and antigen. These findings show that the frequent oscillation in the immune status in immunocompromised individuals can trigger an accelerated virus evolution, thus consolidating this study model as an accelerated pathway to better understand SARS-CoV-2 adaptive traits and anticipate the emergence of variants of concern.


Subject(s)
COVID-19/immunology , Immune Evasion/immunology , Immunocompromised Host/immunology , Lymphoma, Non-Hodgkin/immunology , SARS-CoV-2/immunology , Amino Acids/genetics , Amino Acids/immunology , Animals , COVID-19/virology , Cell Line , Chlorocebus aethiops , Female , Genome, Viral/genetics , Genome, Viral/immunology , Humans , Immune Evasion/genetics , Immunization, Passive/methods , Lymphoma, Non-Hodgkin/virology , Middle Aged , Mutation/genetics , Mutation/immunology , Pandemics/prevention & control , SARS-CoV-2/genetics , Vero Cells , Virus Replication/genetics , Virus Replication/immunology
6.
Journal Health Núcleo de Pesquisa e Extensão em Política, Planejamento, Organização e Práticas (individual e Coletiva) em Saúde ; 5(1):396-416, 2020.
Article in Portuguese | LILACS (Americas) | ID: covidwho-1016720

ABSTRACT

Objetivo: elencar com base nas manifestações clínicas da doença, os principais diagnósticos de enfermagem que podem ser aplicados para crianças, adultos, gestantes e idosos com COVID-19. Método: revisão integrativa da literatura nacional e internacional, realizada no período de março a maio de 2020, a partir do cruzamento entre os termos: "pacientes", "infecções por coronavírus"e "sinais e sintomas", usando o operador booleano and. Selecionou-se 26 estudos, apresentando em quadro. Utilizouse a taxonomia da Associação Norte-Americana de Diagnósticos de Enfermagem e a Classificação Internacional para a Prática de Enfermagem para elencar os diagnósticos pertinentes ao quadro clínico frequentemente presente entre participantes com covid19. Resultados: conforme os sinais e sintomas presentes na fase aguda da doença em pacientes sob internação e em uso de terapia medicamentosa, os diagnósticos predominantes foram proteção ineficaz relacionado à incapacidade de proteção contra agente infeccioso evidenciado por tosse, calafrios e fadiga, presença de tosse, Hipertermia relacionada a processo infeccioso evidenciado por pele quente ao toque, padrão respiratório ineficaz relacionado à dor e fadiga evidenciado por dispneia. Considerações finais: alguns diagnósticos são prevalentes, entretanto, a avaliação deve ser individual, bem como a assistência, baseada nas necessidades de cada indivíduo. Objective: to list, based on the clinical manifestations of the disease, the main nursing diagnoses that can be applied to children, adults, pregnant women and the elderly with COVID-19. Method: integrative review of national and international literature, carried out from March to May 2020, based on the crossing between the terms: "patients", "coronavirus infections"and "signs and symptoms", using the Boolean operator and. 26 studies were selected and presented in a table. The taxonomy of the North American Association of Nursing Diagnoses and the International Classification for Nursing Practice were used to list the diagnoses relevant to the clinical picture frequently present among participants with covid-19. Results: according to the signs and symptoms present in the acute phase of the disease in patients hospitalized and using drug therapy, the prevalent diagnoses were ineffective protection related to the inability to protect against an infectious agent evidenced by cough, chills and fatigue, presence of cough, related hyperthermia an infectious process evidenced by hot skin to the touch, ineffective breathing pattern related to pain and fatigue evidenced by dyspnea. Final considerations: some diagnoses are prevalent, however, the assessment must be individual, as well as assistance, based on the needs of each individual. Objetivo: enumerar, con base en las manifestaciones clínicas de la enfermedad, los principales diagnósticos de enfermería que pueden aplicarse a niños, adultos, mujeres embarazadas y ancianos con COVID-19. Método: revisión integradora de la literatura nacional e internacional, realizada entre marzo y mayo de 2020, basada en el cruce entre los términos: "pacientes", "infecciones por coronavirus"y "signos y síntomas", utilizando el operador booleano y. Se seleccionaron 26 estudios y se presentaron en una tabla. La taxonomía de la Asociación Norteamericana de Diagnósticos de Enfermería y la Clasificación Internacional para la Práctica de Enfermería se utilizaron para enumerar los diagnósticos relevantes para el cuadro clínico frecuentemente presente entre los participantes con covid-19. Resultados: de acuerdo con los signos y síntomas presentes en la fase aguda de la enfermedad en pacientes hospitalizados y que usan terapia farmacológica, los diagnósticos prevalentes fueron protección ineficaz relacionada con la incapacidad de protección contra un agente infeccioso evidenciado por tos, escalofríos y fatiga, presencia de tos, hipertermia relacionada un proceso infeccioso evidenciado por la piel caliente al tacto, un patrón de respiración ineficaz relacionado con el dolor y la fatiga evidenciada por la disnea. Consideraciones finales: algunos diagnósticos son frecuentes, sin embargo, la evaluación debe ser individual, así como asistencia, según las necesidades de cada individuo.

SELECTION OF CITATIONS
SEARCH DETAIL